ICON plc | Clinical Research Organisation (CRO) for Drug Development

Risk Based Quality Management

Essential for a robust monitoring strategy.

The evolution of HIV treatments

From antiretroviral therapy to vaccines, where we are today and what’s next.

ICER’s impact on payer decision making

Results of ICON’s third annual survey.

The IVDR journey

A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

Webinars

Upcoming webinar: Using wearables data to support drug reimbursement

18 May, 2021. Register now.

Long term effects of the COVID-19 pandemic on cardiovascular trial design

Upcoming webinar: Cardiovascular event adjudication during COVID-19 and beyond

21 May, 2021. Register now.

On-demand webinars

Visit our webinar channel to access other recent webinars.

Featured Services

COVID-19 clinical operations

Keeping your clinical trial on track in an evolving environment.

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Biosimilars

ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

20 April 2021

Event report - DIA Europe 2021: Advancing health priorities

Shradha Galaya, Director of Global Safety Regulatory Reporting, reports on the highlights of her recent virtual attendance at DIA Europe 2021.

14 April 2021

Biomarker assays: Bioanalytical meets CLIA

The blog considers current perspectives on the use of biomarkers, differences between the needs of biomarker assays developed for use in bioanalytical labs or clinical labs, and what may be needed in the case that a biomarker assay needs to migrate into a CLIA lab.

08 April 2021

Looking back and looking ahead: Trends in HEOR

In-person research became impossible due to the pandemic, and forced us to re-examine how patient's voices were being captured. In 2021 we continue to build on what we learned.

06 April 2021

Navigating complexity of cell therapy manufacturing during the COVID-19 pandemic

Over the past year, the COVID-19 pandemic significantly disrupted clinical research across the lifecycle including recruitment challenges, protocol amendments and delayed market entry.

05 April 2021

Navigating complexity in oncology cell and gene therapy clinical trials

As more knowledge is revealed about the genetic underpinnings of cancers, cell and gene therapies (CGT) are playing an increasingly important role in treating oncology patients

01 April 2021

Innovation in oncology drug development: A focus on patient benefits

Improved diagnostic technologies, prevention methods and the advent of targeted therapeutic approaches have together contributed to lowering the mortality rate for the 10 most prevalent cancers

29 March 2021

Cell and gene therapy trials - delivering differently

The success of cell and gene therapies (CGT) has transformed the delivery of clinical trial services, requiring the design of new workflows, processes and tools.

24 March 2021

Multidiagnostic approaches for patient selection biomarkers in immuno-oncology

Advances in our understanding of cancer biology and the tumour microenvironment (TME), have led to the development of personalised drug and therapy designs to better prevent disease progression and relapse.

22 March 2021

Briefing: The UK NICE methods of health technology assessment

In a statement on February 2021, the UK’s National Institute for Health and Care Excellence (NICE) launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

ICON to acquire PRA Health Sciences

Clinical Study Match

The voice of NASH investigators

Antimicrobial resistance